Insiders at the Food and Drug Administration are ringing alarm bells over the agency's use of an AI to fast-track drug ...

AI will not replace doctors in a hurry, but platforms like Microsoft AI Diagnostic Orchestrator (MAI-DxO) are improving diagnostic accuracy to levels which is hard to ignore ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ('HeartSciences' or the 'Company'), an artificial intelligence ('AI”)-powered medical technology company transforming ECGs/EKGs to enable earlier detection of ...

But according to three current FDA employees “ELSA” is creating studies that don’t exist. They say that makes it hard to ...

Commissioner Marty Makary says the FDA will plow ahead with big plans on ultra process foods, dietary guidelines and ...

We recently published 12 Stocks Jim Cramer Discussed As Analyzed Morgan Stanley’s Comments. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the stocks Jim Cramer recently discussed.

The White House has released “America’s AI Action Plan,” a national strategy to accelerate AI adoption across key sectors — with healthcare identified as a top priority for reform, innovation and ...

After announcing a $20 million funding round in June, the startup has set its sights on growing its customer-facing workforce ...

The FDA's 'Elsa' AI, intended to speed up drug approvals, is reportedly fabricating studies, part of a wider trend of unreliable AI in high-stakes roles.

Y ou'd have to be a special kind of Luddite to think that artificial intelligence won't change health care. The word ...

The FDA's generative AI, Elsa, has a massive hallucination problem, according to the agency's employees themselves.